Bluebird Bio Has Entered Into An Agreement To Sell A Rare Pediatric Disease Priority Review Voucher (PRV), If Received, In Connection With The Potential Approval Of Lovotibeglogene Autotemcel (Lovo-cel) For Sickle Cell Disease
Bluebird Bio Has Entered Into An Agreement To Sell A Rare Pediatric Disease Priority Review Voucher (PRV), If Received, In Connection With The Potential Approval Of Lovotibeglogene Autotemcel (Lovo-cel) For Sickle Cell Disease
Bluebird Bio已達成協議，如果收到，將出售罕見兒科疾病優先審查券（PRV），該憑證可能獲准用於鐮狀細胞病的Lovotibeglogene Autotemcel（Lovo-cel）
Under the terms of the agreement, rights to the PRV will transfer to the buyer and the Company will receive $103 million upon closing of the sale, which is contingent upon the FDA's approval of the biologics license application (BLA) for lovo-cel and granting of the PRV.
根據協議條款，PRV的權利將轉讓給買方，該公司將在銷售完成後獲得1.03億美元，這取決於美國食品藥品管理局批准lovo-cel的生物製劑許可申請（BLA）並授予PRV。